Recent content by patorjk

It's quoted above. Here are the results and conclusion: It acknowledges there was a placebo effect (something that appears to be true for all tinnitus trials), but it says there is sufficient proof of concept to support future investigation.

Now that this study is over and showed promising results, does anyone know if there is any active research into micro-dosing MDMA as a cure/reducer of tinnitus? For some reason I've been thinking about this the past few days. I've read many reports of the drug reducing tinnitus, and it seems...

Decibel Therapeutics (now owned by Regeneron) has a similar drug and made a press release regarding similarly good news back in October. Both Decibel Therapeutics and Akouos are aiming to tackle smaller hearing diseases as they work their way up to a cure for general hearing loss. This early...

I decided to dig around and see if there was any news from DB-OTO study and I found this press release from Regeneron that indicated some initial success: A placebo effect for this kind of hearing loss is unlikely, especially for a child that probably doesn't even know what's happening. I...

Decibel Therapeutics announced this morning that they're being acquired by Regeneron. The deal is $4 per share plus $3.5 per share in CVR (contingent value right). According to the agreement the CVR is: The first $2 seems pretty likely given that the DB-OTO trial has already started. Hopefully...

About 2 weeks before the FX-322's Phase 2b data release, the CEO retweeted these tweets: I think this gives us the best insight into what he was thinking. Prior to knowing the results, the company probably drew out 2 paths forward: 1) Positive results: Push forward with FX-322 into Phase 3...

Gene therapy is one avenue that's being explored. The two main companies (that I'm aware of) in this space are Decibel Therapeutics and Akouos. Akouos got acquired by Eil Lilly last year for a huge premium, which tells me that the major players see this as a fruitful avenue. Both companies are...

They did a one-year follow up on the Phase 1/2 trial participants and the effects at 90 days had significantly lessened. They did a similar long term follow-up for the Phase 1b open-label study (I think it was at the 6th or 9th month mark) and a similar thing was observed, though I think 1...

He was asked about this on Twitter and replied "No plan to do that. Not convinced that drug delivery was FX-322’s only challenge". I found this kind of interesting since his thread on FX-322 failing focused mostly on drug delivery, and didn't mention anything else. Also of note is that his...

Elsewhere on Twitter he says (in regards to a hearing drug) "We’ve been testing a wide range of approaches in the lab. Might have something ready for the clinic in 2024" and "Biggest challenge is nailing the clinical application. What are relevant endpoints that lead to a reasonable study design...

As I said in my previous post, their current drug candidate, SPT-2101, is dexamethasone - which is what Otonomy's Ovitidex was. If SPT-2101 shows improvements better than Otividex, then their drug delivery tech may be the real deal and there may be some real hope for OTO-413. As for them trying...

I unfortunately can't find any info on it. I did find this press release though, which talks about the Phase 1 and Phase 2 studies of SPT-2101. Further digging shows they have around 18.5M in funding. Their website is really light on info though. I'm guessing they're just too early stage at the...

Great news everyone, the CEO of Spiral Therapeutics just tweeted that their plan is indeed to see if BDNF works with their delivery method. OTO-413 isn't quite dead yet. He said this in a thread where he discussed why he thought FX-322 failed. I wonder if his company will try to acquire the...

They did, but they didn't expect a response from them, they just did them for safety reasons. Here's what they told me when I emailed them back in 2021: Thanks for the question. We are still doing standard audiograms as part of the safety assessment. For preclinical studies, we used auditory...

My guess is they'll take a close look at all of the data they're given to see if they think BDNF is viable to move forward with. I assume they're not going to be using Otonomy's delivery method. There's no way to know though. They only paid $250k for it, so it's kind of like a moonshot for them...